| Denali Has A Neurodegenerative Edge Despite Market Skepticism | 11/16 08:56 | seekingalpha.com |
| Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging | 11/08 11:10 | zacks.com |
| Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | 11/06 16:01 | globenewswire.com |
| Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release | 10/29 11:06 | zacks.com |
| Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? | 09/16 12:26 | zacks.com |
| Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug | 09/04 12:41 | zacks.com |
| Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) | 09/03 08:00 | globenewswire.com |
| Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology | 08/19 22:55 | seekingalpha.com |
| Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration | 08/14 14:00 | globenewswire.com |
| Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade | 08/06 10:55 | zacks.com |